Quadrivalent influenza vaccine: a new opportunity to reduce the influenza burden

scientific article published on January 2016

Quadrivalent influenza vaccine: a new opportunity to reduce the influenza burden is …
instance of (P31):
review articleQ7318358
scholarly articleQ13442814

External links are
P932PMC publication ID4910440
P698PubMed publication ID27346937

P2093author name stringI Barberis
M Martini
F Ansaldi
V Faccio
C Paganino
C Trucchi
V Tisa
P2860cites workGlobal Role and Burden of Influenza in Pediatric Respiratory Hospitalizations, 1982–2012: A Systematic AnalysisQ26751854
Influenza-associated hospitalizations in the United StatesQ29619463
Reassortment and insertion-deletion are strategies for the evolution of influenza B viruses in natureQ33649395
The potential cost-effectiveness of quadrivalent versus trivalent influenza vaccine in elderly people and clinical risk groups in the UK: a lifetime multi-cohort modelQ33721397
Epidemiology and pathogenesis of influenzaQ33907890
Effectiveness of seasonal influenza vaccine in community-dwelling elderly people: a meta-analysis of test-negative design case-control studiesQ34451202
Vaccine recommendations for children and youth for the 2014/2015 influenza seasonQ34453977
Surveillance and vaccine effectiveness of an influenza epidemic predominated by vaccine-mismatched influenza B/Yamagata-lineage viruses in Taiwan, 2011-12 seasonQ34614814
Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 yearsQ34862926
4Flu - an individual based simulation tool to study the effects of quadrivalent vaccination on seasonal influenza in GermanyQ35200964
Cost-effectiveness evaluation of quadrivalent influenza vaccines for seasonal influenza prevention: a dynamic modeling study of Canada and the United KingdomQ35821862
Cost-effectiveness of quadrivalent influenza vaccine in Hong Kong - A decision analysis.Q35886955
Retrospective public health impact of a quadrivalent influenza vaccine in the United States.Q35995259
A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 yearsQ36846234
Post-licensure surveillance of quadrivalent inactivated influenza (IIV4) vaccine in the United States, Vaccine Adverse Event Reporting System (VAERS), July 1, 2013-May 31, 2015Q37027049
Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate: a phase III randomized controlled trial in childrenQ37037095
A comprehensive review of the epidemiology and disease burden of Influenza B in 9 European countriesQ37130821
The rationale for quadrivalent influenza vaccinesQ37976542
The evolving history of influenza viruses and influenza vaccinesQ38136296
Influenza B viruses: not to be discountedQ38584342
Evidence update: GlaxoSmithKline's inactivated quadrivalent influenza vaccines.Q38660898
Immunogenicity and safety of a quadrivalent live attenuated influenza vaccine in childrenQ40291541
Effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2014/15 end of season resultsQ40357312
Cost-effectiveness analysis of quadrivalent influenza vaccination in at-risk adults and the elderly: an updated analysis in the U.K.Q41026843
Increased prevalence of influenza B/Victoria lineage viruses during early stages of the 2015 influenza season in New South Wales, Australia: implications for vaccination and planning.Q41042952
Post-marketing surveillance of adverse events following immunization with inactivated quadrivalent and trivalent influenza vaccine in health care providers in Western AustraliaQ41206726
Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2015-16 Influenza SeasonQ41510283
Immunogenicity and safety of inactivated quadrivalent and trivalent influenza vaccines in children 18-47 months of age.Q42181750
Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adultsQ42271180
Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983.Q43207722
Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004-2005 season to the 2006-2007 seasonQ46159620
Molecular characterization of influenza B viruses circulating in northern Italy during the 2001-2002 epidemic seasonQ73437339
P275copyright licenseCreative Commons Attribution-NonCommercial-NoDerivs 3.0 UnportedQ19125045
P433issue1
P921main subjectinfluenzaQ2840
influenza vaccineQ383260
influenza A virusQ834390
Influenza B virusQ1089532
P5008on focus list of Wikimedia projectScienceSourceQ55439927
P304page(s)E28-33
P577publication date2016-01-01
P1433published inJournal of preventive medicine and hygieneQ26842091
P1476titleQuadrivalent influenza vaccine: a new opportunity to reduce the influenza burden
P478volume57

Reverse relations

cites work (P2860)
Q39397313A Perspective on the Structural and Functional Constraints for Immune Evasion: Insights from Influenza Virus
Q55094530A systematic review and meta-analysis of the direct epidemiological and economic effects of seasonal influenza vaccination on healthcare workers.
Q64246989Awareness and acceptance of H1N1 vaccination among physicians: Experience of 2017 vaccination campaign
Q89720566Better influenza vaccines: an industry perspective
Q89965369Broadly Protective Strategies Against Influenza Viruses: Universal Vaccines and Therapeutics
Q92360676Cell-Based Quadrivalent Inactivated Influenza Virus Vaccine (Flucelvax® Tetra/Flucelvax Quadrivalent®): A Review in the Prevention of Influenza
Q64245823Circulation of influenza A and B in the Czech Republic from 2000-2001 to 2015-2016
Q56536297Clinical Expectations for Better Influenza Virus Vaccines-Perspectives from the Young Investigators' Point of View
Q57210543Cost Effectiveness of Quadrivalent Influenza Vaccines Compared with Trivalent Influenza Vaccines in Young Children and Older Adults in Korea
Q92023401Divergent evolutionary trajectories of influenza B viruses underlie their contemporaneous epidemic activity
Q37669436Fifteen years of epidemiologic, virologic and syndromic influenza surveillance: A focus on type B virus and the effects of vaccine mismatch in Liguria region, Italy.
Q28079669History and evolution of influenza control through vaccination: from the first monovalent vaccine to universal vaccines
Q91989762Identification of Rare Adverse Events with Year-varying Reporting Rates for FLU4 Vaccine in VAERS
Q52655883Immunogenicity of Quadrivalent Influenza Vaccine for Patients with Inflammatory Bowel Disease Undergoing Immunosuppressive Therapy.
Q52599675Novel Platforms for the Development of a Universal Influenza Vaccine.
Q38375170Pharmacokinetics of MHAA4549A, an Anti-Influenza A Monoclonal Antibody, in Healthy Subjects Challenged with Influenza A Virus in a Phase IIa Randomized Trial
Q55038946Safety and Immunogenicity of an Egg-Cultivated Quadrivalent Inactivated Split-virion Influenza Vaccine (GC3110A) in Healthy Korean Children: a Randomized, Double-blinded, Active-controlled Phase III Study.
Q88642245Sustainable vaccine development: a vaccine manufacturer's perspective
Q94545406Vaccines to Prevent Infectious Diseases in the Older Population: Immunological Challenges and Future Perspectives